MYC and acute lymphoblastic leukemia: In agreement, in vivo treatment with JQ1 and A-485 inhibitors caused reduced BRD recruitment on enhancers and downregulation of Myc expression, indicating p300 or BRD proteins as potential therapeutic target for ALL.